These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Comparison of anti-HBV vaccine efficacy given intradermally and intramuscularly in hemodialysis patients].
    Author: Miłkowski A, Wyrwicz G, Kubit P, Smoleński O.
    Journal: Przegl Lek; 2000; 57(11):628-34. PubMed ID: 11293210.
    Abstract:
    Patients chronically hemodialysed are recognised as a group of especially high risk for viral hepatitis B (HBV) infection. Moreover, their hyporesponsiveness to vaccination is widely known. So establishment of highly effective vaccination protocol is indispensable. We are presenting 5 year prospective observations of results of hemodialysis patients anti-HBV vaccination. 36 patients were vaccinated intramuscularly (among them 30 were revaccinated intradermally) and 40 patients--only intradermally. We revealed that seroprotective level of anti-HBs antibodies should be at least 100 IU/ml. We disclosed, that intradermal anti-HBV vaccination--compared to intramuscular--was significantly more effective (77.5%--and including answer in the second vaccination cycle 85.0%--vs 38.9%) and, moreover, less amount of vaccine could be used (28.2 micrograms--and for patients answering barely in the second vaccination cycle 53.7 micrograms--vs 123 micrograms). However, after intradermal vaccination seroprotective antibodies level falls faster and should be checked every 3 months. Patients answering efficiently to vaccination--comparing to answering inefficiently--have significantly higher albumin level and are younger. Moreover, higher dialysis dose favors the successful long-time answer to vaccination.
    [Abstract] [Full Text] [Related] [New Search]